Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director | May 29, 2026 | June 01, 2026 |
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Director | June 13, 2019 | June 14, 2019 |
| INCYTE CORPINCY · Entity 3182 | Director | September 30, 2026 | October 03, 2026 |
| Karuna Therapeutics, Inc.KRTX · Entity 92934 | Director | August 12, 2020 | August 14, 2020 |
| PhaseBio Pharmaceuticals IncPHAS · Entity 113305 | Director | May 19, 2023 | May 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date May 29, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,148 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Exercise / conversion · Acquired 8,107 · Balance 43,148 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Exercise / conversion · Disposed 8,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,311 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Grant · Acquired 9,311 · Balance 9,311 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2036-05-28 | Direct | 16,004 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 16,004 · Balance 16,004 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.
BELLICUM PHARMACEUTICALS, INC
Report date June 13, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2029-06-12 | Direct | 25,000 |
Reported balance
After 2019-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-13 · Grant · Acquired 25,000 · Balance 25,000 F1: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date.
INCYTE CORP
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,225 |
Reported balance
After 2026-09-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 206 · Balance 23,225 F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2: This includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.
F2: This includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Karuna Therapeutics, Inc.
Report date August 12, 2020 · Filed August 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,163 |
Reported balance
After 2020-08-12 transaction · row 1
1 source rowRow 1 · 2020-08-12 · Sale · Disposed 10,000 · Balance 55,163 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
PhaseBio Pharmaceuticals Inc
Report date May 19, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,750 |
Reported balance
After 2023-05-19 transaction · row 1
1 source rowRow 1 · 2023-05-19 · Exercise / conversion · Acquired 3,750 · Balance 9,750 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-19 · Exercise / conversion · Acquired 3,750 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:02 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 206 | $121.35 | $24,998.10 |
DisclosureSEC source: 0001177917-26-000014 · wk-form4_1790971323.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,225 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:07 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 255 | $113.36 | $28,906.80 |
DisclosureSEC source: 0001177917-26-000012 · wk-form4_1783022833.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,019 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon Qualfied Stock Option (right to buy) · Derivative | 6,111 | $0.00 Strike: $100.64 | $0.00 |
DisclosureSEC source: 0001177917-26-000011 · wk-form4_1781122095.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,111 Underlying: Common Stock · 6,111 shares Expires 2036-06-07 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001177917-26-000011 · wk-form4_1781122095.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,764 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 9,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001177917-26-000009 · form4-06012026_060612.xml · derivative · entry 4 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,311 Underlying: Common Stock · 9,311 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 16,004 | $0.00 Strike: $21.66 | $0.00 |
DisclosureSEC source: 0001177917-26-000009 · form4-06012026_060612.xml · derivative · entry 3 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,004 Underlying: Common Stock · 16,004 shares Expires 2036-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 8,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001177917-26-000009 · form4-06012026_060612.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001177917-26-000009 · form4-06012026_060612.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:10 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 269 | $94.12 | $25,318.28 |
DisclosureSEC source: 0001177917-26-000006 · wk-form4_1775160612.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,122 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 245 | $98.77 | $24,198.65 |
DisclosureSEC source: 0001177917-26-000002 · wk-form4_1767647141.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,853 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 289 | $84.81 | $24,510.09 |
DisclosureSEC source: 0001177917-25-000004 · wk-form4_1759435730.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,608 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:44 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 367 | $68.10 | $24,992.70 |
DisclosureSEC source: 0000879169-25-000069 · wk-form4_1751489017.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,319 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon Qualfied Stock Option (right to buy) · Derivative | 9,216 | $0.00 Strike: $70.07 | $0.00 |
DisclosureSEC source: 0001628280-25-030999 · wk-form4_1749760072.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,216 Underlying: Common Stock · 9,216 shares Expires 2035-06-09 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-030999 · wk-form4_1749760072.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,952 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015273 · form4-06022025_060607.xml · derivative · entry 4 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,107 Underlying: Common Stock · 8,107 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 13,793 | $0.00 Strike: $22.29 | $0.00 |
DisclosureSEC source: 0001415889-25-015273 · form4-06022025_060607.xml · derivative · entry 3 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,793 Underlying: Common Stock · 13,793 shares Expires 2035-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015273 · form4-06022025_060607.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015273 · form4-06022025_060607.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 363 | $60.55 | $21,979.65 |
DisclosureSEC source: 0001628280-25-016170 · wk-form4_1743624329.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,434 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 18:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 339 | $69.07 | $23,414.73 |
DisclosureSEC source: 0000879169-25-000003 · wk-form4_1735927555.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,071 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 17:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 378 | $66.10 | $24,985.80 |
DisclosureSEC source: 0000879169-24-000158 · wk-form4_1727888444.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,732 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 17:22 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 409 | $60.62 | $24,793.58 |
DisclosureSEC source: 0000879169-24-000101 · wk-form4_1719940925.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,354 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:14 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon Qualfied Stock Option (right to buy) · Derivative | 12,517 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0000879169-24-000092 · wk-form4_1718381636.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,517 Underlying: Common Stock · 12,517 shares Expires 2034-06-11 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:14 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,830 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000092 · wk-form4_1718381636.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,945 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 9,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015086 · form4-05312024_060509.xml · derivative · entry 4 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,387 Underlying: Common Stock · 9,387 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 15,959 | $0.00 Strike: $14.62 | $0.00 |
DisclosureSEC source: 0001415889-24-015086 · form4-05312024_060509.xml · derivative · entry 3 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,959 Underlying: Common Stock · 15,959 shares Expires 2034-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015086 · form4-05312024_060509.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-015086 · form4-05312024_060509.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| March 28, 2024 Filed Apr 2, 2024 16:12 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 413 | $56.97 | $23,528.61 |
DisclosureSEC source: 0000879169-24-000069 · wk-form4_1712074328.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,115 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,505 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 17:07 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 423 | $62.79 | $26,560.17 |
DisclosureSEC source: 0000879169-24-000003 · wk-form4_1704301653.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,702 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,505 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 389 | $57.77 | $22,472.53 |
DisclosureSEC source: 0000879169-23-000031 · wk-form4_1696363547.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,279 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,505 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 390 | $62.25 | $24,277.50 |
DisclosureSEC source: 0001209191-23-040945 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,890 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,505 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,294 | $0.00 Strike: $61.44 | $0.00 |
DisclosureSEC source: 0001209191-23-037799 · doc4.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,294 Underlying: Common Stock · 11,294 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037799 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 6,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034696 · doc4.xml · derivative · entry 8 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,652 Underlying: Common Stock · 6,652 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 11,045 | $0.00 Strike: $23.90 | $0.00 |
DisclosureSEC source: 0001209191-23-034696 · doc4.xml · derivative · entry 7 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,045 Underlying: Common Stock · 11,045 shares Expires 2033-05-31 F3 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 8,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034696 · doc4.xml · derivative · entry 6 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,552 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034696 · doc4.xml · nonDerivative · entry 3 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| May 19, 2023 Filed May 19, 2023 16:17 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001169245-23-000030 · wf-form4_168452744179673.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2 · derivative.exercise_date: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. F2 · derivative.expiration_date: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2023 Filed May 19, 2023 16:17 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001169245-23-000030 · wf-form4_168452744179673.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 326 | $72.27 | $23,560.02 |
DisclosureSEC source: 0001209191-23-022634 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,995 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:02 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 302 | $80.32 | $24,256.64 |
DisclosureSEC source: 0001209191-23-000800 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,669 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 165 | $69.59 | $11,482.35 |
DisclosureSEC source: 0001209191-22-054184 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,367 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly Board committee retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:03 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 250 | $66.64 | $16,660.00 |
DisclosureSEC source: 0001209191-22-052166 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,202 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 236 | $75.97 | $17,928.92 |
DisclosureSEC source: 0001209191-22-040184 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,952 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,124 | $0.00 Strike: $68.55 | $0.00 |
DisclosureSEC source: 0001209191-22-037798 · doc4.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,124 Underlying: Common Stock · 9,124 shares Expires 2032-06-14 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,144 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037798 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,716 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 00:27 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035666 · doc4.xml · derivative · entry 2 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,552 Underlying: Common Stock · 8,552 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 00:27 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 14,368 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001209191-22-035666 · doc4.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,368 Underlying: Common Stock · 14,368 shares Expires 2032-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 07, 2022 Filed Jun 6, 2023 01:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034696 · doc4.xml · derivative · entry 5 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.